U.S., Sept. 16 -- ClinicalTrials.gov registry received information related to the study (NCT07821424) titled 'Wucao Anfu Formula as Adjunctive Treatment for Immune Checkpoint Inhibitor-Related Rash' on Sept. 10.
Brief Summary: Immune checkpoint inhibitors have improved outcomes for patients with cancer, but immune checkpoint inhibitor-related skin rash is a common adverse event that may affect quality of life and continuation of anticancer therapy. This study aims to evaluate the efficacy and safety of Wucao Anfu Formula as an adjunctive treatment for immune checkpoint inhibitor-related rash. In this randomized controlled clinical study, eligible patients with grade 1-2 immune checkpoint inhibitor-related rash will be randomly assigned to ...